Growth and capacity leveraged by HTL-STREFA as part of MTD Group’s expansion into Continuous Glucose Monitoring Systems and expanded pen needle production capacity, presenting cross-sell opportunities for advanced device components, consumables, and integrated supply chain services across Europe and North America.

Strategic partnerships integration with Ypsomed’s pen needles operations broadens European production and distribution reach, signaling opportunities to propose bundled procurement, co-branding, and joint go-to-market initiatives to accelerate penetration in existing and new markets.

Safety leadership HTL-STREFA’s leading position in safety lancets and safety pen needles creates openings to upsell complementary safety-engineered devices, training programs, and safety compliance solutions to healthcare providers and clinics prioritizing needlestick prevention.

Digital and analytics mention of IoT, data analytics, and cloud capabilities within MTD Group suggests potential for selling connected device ecosystems, telemetry, usage analytics, and remote monitoring services to optimize inventory, manufacturing, and clinical workflows.

Global reach presence with production facilities in Europe and distribution in Europe and the USA, plus a growing brand footprint with Droplet as a top pen needle supplier, indicates opportunities for channel partnerships, regional deployments, and multilingual sales efforts to accelerate market share in key regions.